Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and its executives violated the Securities Exchange Act of 1934, with claims centered around misleading statements regarding the efficacy of their drug candidate sonelokimab (SLK) compared to a competitor's product [1][3][4]. Group 1: Lawsuit Details - The lawsuit is titled Peters v. MoonLake Immunotherapeutics and is filed in the Southern District of New York [1]. - The class action seeks to represent purchasers or acquirers of MoonLake common stock during the class period [1][2]. - The lead plaintiff motions must be filed by December 15, 2025 [2]. Group 2: Company and Product Information - MoonLake is a clinical stage biotechnology company focused on therapies for inflammatory skin and joint diseases [3]. - SLK is the company's sole drug candidate, primarily developed for treating hidradenitis suppurativa (HS) [3]. Group 3: Allegations Against MoonLake - The lawsuit claims that MoonLake made false statements regarding SLK's clinical benefits, asserting that SLK and BIMZELX share the same molecular targets and that SLK's unique structure would not provide superior efficacy [4]. - On September 28, 2025, MoonLake announced Phase 3 VELA program results indicating SLK did not demonstrate competitive efficacy against BIMZELX, leading to a nearly 90% drop in stock price [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 15, 2025 [3][5]. - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements achieved [4].

Core Viewpoint - MoonLake Immunotherapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, indicating potential concerns regarding the company's performance and transparency [1][3]. Group 1: Company Overview - MoonLake Immunotherapeutics, Inc. is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Group 2: Legal Context - Investors have until December 15, 2025, to file a lead plaintiff motion in the class action lawsuit [1]. - The lawsuit suggests that SLK's commercial prospects hinge on its efficacy in treating HS, which is compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for the same condition [3]. Group 3: Investor Communication - Investors are encouraged to contact attorney Lesley F. Portnoy for legal rights discussions and to explore options for recovering losses [2][4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) for the period between March 10, 2024, and September 29, 2025, due to alleged misleading statements and failure to disclose material facts regarding the company's products [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that during the Class Period, defendants made false and/or misleading statements about the differences between Nanobodies and monoclonal antibodies, specifically regarding SLK and BIMZELX [5]. - Allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's Nanobody structure does not provide superior clinical benefits over traditional monoclonal antibodies [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [5]. Group 2: Participation Information - Investors who purchased MoonLake common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - The MoonLake class action lawsuit alleges that MoonLake Immunotherapeutics and certain executives violated the Securities Exchange Act of 1934, impacting investors who purchased or acquired its common stock [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on developing therapies for inflammatory skin and joint diseases [3]. - The company's primary drug candidate is sonelokimab (SLK), aimed at treating hidradenitis suppurativa (HS) [3]. Allegations - The lawsuit claims that during the class period, MoonLake made false or misleading statements and failed to disclose critical information regarding SLK's efficacy compared to Union Chimique Belge's BIMZELX, an FDA-approved monoclonal antibody for HS [4]. - Specific allegations include that SLK and BIMZELX target the same inflammatory cytokines (IL-17A and IL-17F), and that SLK's unique Nanobody structure does not provide a clinical advantage over BIMZELX [4]. Stock Performance Impact - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, which indicated SLK did not demonstrate competitive efficacy against BIMZELX, MoonLake's stock price plummeted nearly 90% [5]. Legal Process - Investors who suffered substantial losses and wish to serve as lead plaintiff in the class action lawsuit must file motions by December 15, 2025 [2][6]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has a strong track record, being ranked 1 in securing monetary relief for investors in securities class action cases [7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, claiming strong clinical data from its Phase 2 MIRA trial that suggested higher clinical responses and differentiation from competitors [4]. - Allegations have emerged that the clinical data and Nanobody structure of sonelokimab do not provide a superior clinical benefit compared to competitors, raising concerns about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share within a few days [6].

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired common stock of MoonLake Immunotherapeutics between March 10, 2024, and September 29, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding the company's sole drug candidate, sonelokimab (SLK), which was claimed to be superior to competing monoclonal antibody drugs [3] Legal Proceedings - Investors wishing to serve as lead plaintiff must file papers by December 15, 2025, and representation is on a contingency fee basis, meaning shareholders pay no fees or expenses [4] - The law firm Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of MoonLake Immunotherapeutics common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and statements [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit claims that the defendants made false or misleading statements regarding the efficacy and clinical benefits of their product SLK compared to traditional monoclonal antibodies [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]. - A lead plaintiff must move the Court by December 15, 2025, to represent other class members in the litigation [1][3]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - No class has been certified yet, meaning investors are not represented unless they retain counsel [7]. - Investors can choose to remain absent from the class and still have the potential to share in any future recovery [7].

Core Viewpoint - MoonLake Immunotherapeutics is under investigation for potential violations of federal securities laws, which may have impacted investors negatively [1]. Company Investigation - The Law Offices of Frank R. Cruz are leading the investigation on behalf of investors who may have suffered losses related to MoonLake Immunotherapeutics [1]. - The investigation was prompted by a disappointing announcement made by the company on September 28, 2025 [1].

Core Viewpoint - An investigation has been announced regarding MoonLake Immunotherapeutics for potential violations of federal securities laws, indicating possible legal issues that could affect investors [1]. Company Summary - MoonLake Immunotherapeutics is under scrutiny for its compliance with federal securities regulations, which may have implications for its investors [1]. - The Law Offices of Howard G. Smith are reaching out to investors who have experienced losses in MoonLake (MLTX) to discuss potential claims for recovery [1].